Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1997 Jul;63(1):28–34. doi: 10.1136/jnnp.63.1.28

A randomised clinical trial comparing interferon-α and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM

X Mariette 1, C Chastang 1, J Louboutin 1, J Leger 1, P Clavelou 1, J Brouet 1
PMCID: PMC2169620  PMID: 9221964

Abstract

OBJECTIVES—The polyneuropathy associated with a monoclonal IgM directed to the myelin associated glycoprotein (MAG) is a specific entity with a putative causal link between the IgM and the neuropathy. The small benefit offered by alkylating agents or plasma exchanges in these patients justifies the search for alternative treatments.
METHODS—A 12 month multicentre, prospective, randomised, open clinical trial was carried out comparing intravenous immunoglobulin (IVIg; 2g/kg and then 1 g/kg every three weeks) and recombinant interferon-α (IFN-α; 3 MU/m2 subcutaneously three times weekly). The main end point was a clinical neuropathy disability score (CNDS) after six months of treatment. Twenty patients were enrolled; 10 were assigned to IVIg and 10 to IFN-α. 
RESULTS—At six months, one out of 10 patients treated with IVIg had a CNDS improvement of more than 20% whereas eight out of 10 patients treated with IFN-α had such an improvement (P=0.005). The mean CNDS worsened by 2.3 (SD 7.6) (8%) in the IVIg group whereas it improved by 7.5 (SD 11.1) (31%) in the IFN-α group (P=0.02). This improvement persisted after 12 months and was mainly related to an improvement of the sensory component (P=0.02) whereas the motor component was unchanged (P=0.39). Electrophysiological data did not show improvement of motor nerve conduction velocities whereas sensory nerve conduction velocities improved in the upper limbs. A decrease in the level of the monoclonal IgM was seen in two patients treated with IFN-α. At the end of the treatment, antibody activity to MAG was still detected in the serum of all patients.
CONCLUSION—IVIg, as used in this study, did not improve patients with polyneuropathy and monoclonal IgM. By contrast, although its mechanism of action remains to be fully elucided, IFN-α was effective in eight out of 10 patients at six months.



Full Text

The Full Text of this article is available as a PDF (131.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bollensen E., Steck A. J., Schachner M. Reactivity with the peripheral myelin glycoprotein P0 in serum from patients with monoclonal IgM gammopathy and polyneuropathy. Neurology. 1988 Aug;38(8):1266–1270. doi: 10.1212/wnl.38.8.1266. [DOI] [PubMed] [Google Scholar]
  2. Bonomo L., Casato M., Afeltra A., Caccavo D. Treatment of idiopathic mixed cryoglobulinemia with alpha interferon. Am J Med. 1987 Oct;83(4):726–730. doi: 10.1016/0002-9343(87)90904-1. [DOI] [PubMed] [Google Scholar]
  3. Braun P. E., Frail D. E., Latov N. Myelin-associated glycoprotein is the antigen for a monoclonal IgM in polyneuropathy. J Neurochem. 1982 Nov;39(5):1261–1265. doi: 10.1111/j.1471-4159.1982.tb12563.x. [DOI] [PubMed] [Google Scholar]
  4. Cook D., Dalakas M., Galdi A., Biondi D., Porter H. High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology. 1990 Feb;40(2):212–214. doi: 10.1212/wnl.40.2.212. [DOI] [PubMed] [Google Scholar]
  5. Dancea S., Dellagi K., Renaud F., Mahouy G., Hauw J. J., Brouet J. C. Effect of passive transfer of human anti-myelin-associated glycoprotein IgM in marmoset. Autoimmunity. 1989;3(1):29–37. doi: 10.3109/08916938909043611. [DOI] [PubMed] [Google Scholar]
  6. Dellagi K., Dupouey P., Brouet J. C., Billecocq A., Gomez D., Clauvel J. P., Seligmann M. Waldenström's macroglobulinemia and peripheral neuropathy: a clinical and immunologic study of 25 patients. Blood. 1983 Aug;62(2):280–285. [PubMed] [Google Scholar]
  7. Dyck P. J., Daube J., O'Brien P., Pineda A., Low P. A., Windebank A. J., Swanson C. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986 Feb 20;314(8):461–465. doi: 10.1056/NEJM198602203140801. [DOI] [PubMed] [Google Scholar]
  8. Dyck P. J., Low P. A., Windebank A. J., Jaradeh S. S., Gosselin S., Bourque P., Smith B. E., Kratz K. M., Karnes J. L., Evans B. A. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med. 1991 Nov 21;325(21):1482–1486. doi: 10.1056/NEJM199111213252105. [DOI] [PubMed] [Google Scholar]
  9. Dyck P. J., Sherman W. R., Hallcher L. M., Service F. J., O'Brien P. C., Grina L. A., Palumbo P. J., Swanson C. J. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol. 1980 Dec;8(6):590–596. doi: 10.1002/ana.410080608. [DOI] [PubMed] [Google Scholar]
  10. Fest T., de Wazières B., Lamy B., Maskani M., Vuitton D., Dupond J. L. Successful response to alpha-interferon 2b in a refractory IgM autoagglutinin-mediated hemolytic anemia. Ann Hematol. 1994 Sep;69(3):147–149. doi: 10.1007/BF01695696. [DOI] [PubMed] [Google Scholar]
  11. Gastineau D. A., Habermann T. M., Hermann R. C. Severe neuropathy associated with low-dose recombinant interferon-alpha. Am J Med. 1989 Jul;87(1):116–116. doi: 10.1016/s0002-9343(89)80498-x. [DOI] [PubMed] [Google Scholar]
  12. Gutterman J. U. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1198–1205. doi: 10.1073/pnas.91.4.1198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hauttecoeur B., Schmitt C., Dubois C., Danon F., Brouet J. C. Reactivity of human monoclonal IgM with nerve glycosphingolipids. Clin Exp Immunol. 1990 May;80(2):181–185. doi: 10.1111/j.1365-2249.1990.tb05230.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hays A. P., Latov N., Takatsu M., Sherman W. H. Experimental demyelination of nerve induced by serum of patients with neuropathy and an anti-MAG IgM M-protein. Neurology. 1987 Feb;37(2):242–256. doi: 10.1212/wnl.37.2.242. [DOI] [PubMed] [Google Scholar]
  15. Jauberteau M. O., Henin D., Bouche P., Vallat J. M., Dumas M., Dellagi S., Leger J. M., Harpin M. L., Ratinahirana H., Chaunu M. P. Etude des anticorps antiglycolipides au cours des dysglobulinémies monoclonales à IgM associées à une neuropathie périphérique. Rev Neurol (Paris) 1988;144(8-9):474–480. [PubMed] [Google Scholar]
  16. Kanda T., Yoshino H., Ariga T., Yamawaki M., Yu R. K. Glycosphingolipid antigens in cultured bovine brain microvascular endothelial cells: sulfoglucuronosyl paragloboside as a target of monoclonal IgM in demyelinative neuropathy [corrected]. J Cell Biol. 1994 Jul;126(1):235–246. doi: 10.1083/jcb.126.1.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Latov N., Sherman W. H., Nemni R., Galassi G., Shyong J. S., Penn A. S., Chess L., Olarte M. R., Rowland L. P., Osserman E. F. Plasma-cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral-nerve myelin. N Engl J Med. 1980 Sep 11;303(11):618–621. doi: 10.1056/NEJM198009113031105. [DOI] [PubMed] [Google Scholar]
  18. Leger J. M., Younes-Chennoufi A. B., Chassande B., Davila G., Bouche P., Baumann N., Brunet P. Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. J Neurol Neurosurg Psychiatry. 1994 Nov;57 (Suppl):46–49. doi: 10.1136/jnnp.57.suppl.46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Levy Y., Fermand J. P., Navarro S., Schmitt C., Vainchenker W., Seligmann M., Brouet J. C. Interleukin 6 dependence of spontaneous in vitro differentiation of B cells from patients with IgM gammapathy. Proc Natl Acad Sci U S A. 1990 May;87(9):3309–3313. doi: 10.1073/pnas.87.9.3309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Mendell J. R., Sahenk Z., Whitaker J. N., Trapp B. D., Yates A. J., Griggs R. C., Quarles R. H. Polyneuropathy and IgM monoclonal gammopathy: studies on the pathogenetic role of anti-myelin-associated glycoprotein antibody. Ann Neurol. 1985 Mar;17(3):243–254. doi: 10.1002/ana.410170305. [DOI] [PubMed] [Google Scholar]
  21. Misiani R., Bellavita P., Fenili D., Vicari O., Marchesi D., Sironi P. L., Zilio P., Vernocchi A., Massazza M., Vendramin G. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med. 1994 Mar 17;330(11):751–756. doi: 10.1056/NEJM199403173301104. [DOI] [PubMed] [Google Scholar]
  22. Monaco S., Bonetti B., Ferrari S., Moretto G., Nardelli E., Tedesco F., Mollnes T. E., Nobile-Orazio E., Manfredini E., Bonazzi L. Complement-mediated demyelination in patients with IgM monoclonal gammopathy and polyneuropathy. N Engl J Med. 1990 Mar 8;322(10):649–652. doi: 10.1056/NEJM199003083221002. [DOI] [PubMed] [Google Scholar]
  23. Nobile-Orazio E., Baldini L., Barbieri S., Marmiroli P., Spagnol G., Francomano E., Scarlato G. Treatment of patients with neuropathy and anti-MAG IgM M-proteins. Ann Neurol. 1988 Jul;24(1):93–97. doi: 10.1002/ana.410240118. [DOI] [PubMed] [Google Scholar]
  24. Oksenhendler E., Chevret S., Léger J. M., Louboutin J. P., Bussel A., Brouet J. C. Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry. 1995 Sep;59(3):243–247. doi: 10.1136/jnnp.59.3.243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Rotoli B., De Renzo A., Frigeri F., Buffardi S., Marcenò R., Cavallaro A. M., Ruggeri P., Liso V., Musto P., Andriani A. A phase II trial on alpha-interferon (alpha IFN) effect in patients with monoclonal IgM gammopathy. Leuk Lymphoma. 1994 May;13(5-6):463–469. doi: 10.3109/10428199409049636. [DOI] [PubMed] [Google Scholar]
  26. Shenoy M., Baron S., Wu B., Goluszko E., Christadoss P. IFN-alpha treatment suppresses the development of experimental autoimmune myasthenia gravis. J Immunol. 1995 Jun 1;154(11):6203–6208. [PubMed] [Google Scholar]
  27. Smith I. S., Kahn S. N., Lacey B. W., King R. H., Eames R. A., Whybrew D. J., Thomas P. K. Chronic demyelinating neuropathy associated with benign IgM paraproteinaemia. Brain. 1983 Mar;106(Pt 1):169–195. doi: 10.1093/brain/106.1.169. [DOI] [PubMed] [Google Scholar]
  28. Steck A. J., Murray N., Dellagi K., Brouet J. C., Seligmann M. Peripheral neuropathy associated with monoclonal IgM autoantibody. Ann Neurol. 1987 Dec;22(6):764–767. doi: 10.1002/ana.410220614. [DOI] [PubMed] [Google Scholar]
  29. Tatum A. H. Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti-myelin-associated glycoprotein. Ann Neurol. 1993 May;33(5):502–506. doi: 10.1002/ana.410330514. [DOI] [PubMed] [Google Scholar]
  30. Upadhyaya G., Guba S. C., Sih S. A., Feinberg A. P., Talpaz M., Kantarjian H. M., Deisseroth A. B., Emerson S. G. Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J Clin Invest. 1991 Dec;88(6):2131–2136. doi: 10.1172/JCI115543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. van Doorn P. A., Brand A., Strengers P. F., Meulstee J., Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology. 1990 Feb;40(2):209–212. doi: 10.1212/wnl.40.2.209. [DOI] [PubMed] [Google Scholar]
  32. van der Meché F. G., Schmitz P. I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med. 1992 Apr 23;326(17):1123–1129. doi: 10.1056/NEJM199204233261705. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES